<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250211</url>
  </required_header>
  <id_info>
    <org_study_id>CNS-09-0027 / ethics 21780</org_study_id>
    <nct_id>NCT00250211</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide</brief_title>
  <official_title>Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a
      tumor more accurately allowing a more targeted delivery of radiation. The investigators hope
      to learn whether tomotherapy will be able to deliver higher radiation doses safely to the
      tumor while sparing the surrounding normal tissue.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine tumor response and pattern of failure using functional MRI imaging</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to disease progression</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distinguish residual tumor from treatment-related necrosis</measure>
    <time_frame>study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute late toxicity of tomotherapy and hypofractionation</measure>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Glioma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional MRI imaging and tomotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed glioblastoma multiforme

          -  Ages 18-65

          -  Karnofsky Performance Scale (KPS) equal to or less than 70

          -  Minimal neurological deficit

          -  Eligible for concurrent temozolomide chemotherapy

        Exclusion Criteria:

          -  Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bassam Abdulkarim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging, functional</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>temozolomide</keyword>
  <keyword>functional imaging</keyword>
  <keyword>concurrent chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

